Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Same-Day Pegfilgrastim-cbqv Administration Is Feasible in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy Regimens

2021 Year in Review - Biosimilars - Biosimilars

The findings from a small, retrospective study suggest that same-day pegfilgrastim-cbqv was a safe and effective alternative to standard administration 24 hours postchemotherapy for the primary and secondary prophylaxis of febrile neutropenia with myelosuppressive chemotherapy in patients with breast cancer.

The standard of care for the primary or secondary prophylaxis of febrile neutropenia (FN) following myelosuppressive chemotherapy has been the administration of long-acting injectable granulocyte colony-stimulating factor, pegfilgrastim, and its biosimilars 24 hours postchemotherapy. With the intent of reducing potential patient exposure to SAR-CoV-2, same-day administration of injectable pegfilgrastim-cbqv was implemented among select patients with breast cancer receiving myelosuppressive chemotherapy regimens. A retrospective study assessed the incidence and severity of FN following same-day administration of injectable pegfilgrastim-cbqv.

In this study, retrospective electronic health record chart reviews identified 55 patients with breast cancer who received same-day pegfilgrastim-cbqv administration for primary or secondary prophylaxis following myelosuppressive chemotherapy. Eligible patients must have completed ≥2 consecutive cycles of same-day pegfilgrastim-cbqv 6-mg subcutaneous injection. The median age of the patient cohort was 49.1 years (range, 29-71 years) and the majority were white (56.4%).

Overall, 9 (16.4%) of the 55 patients experienced FN (grade 3/4) and 6 (10.9%) patients were hospitalized. Of these, the majority of patients (88.9%) experienced FN between cycles 1 and 2. There were no grade 5 events and no patient discontinued treatment because of FN.

Based on this retrospective data analysis, albeit in a small cohort of patients with breast cancer, the authors concluded that same-day pegfilgrastim-cbqv was a safe and effective alternative in the primary and secondary prophylaxis of FN with myelosuppressive chemotherapy used in breast cancer treatment.

Source: Leiva M, Pennisi A, Kiernan Harnden K, et al. The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center. J Clin Oncol. 2021;39(suppl_15):e18687.

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
2021 in Review
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Incidence of Hypertension and Proteinuria in Bevacizumab- and Bevacizumab Biosimilar-Treated Cohorts
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Evidence of Cardiac Safety of Trastuzumab Biosimilar Trastuzumab-anns in Breast Cancer
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Evidence of Bevacizumab-awwb Use in a Population of Patients with Cancer
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.